Mein Warenkorb

Integrin alpha 2b beta 3

Integrin alpha 2b beta 3 Molekülinformation

Englischer NameIntegrin alpha-IIb/beta-3Anzahl der inverkehr gebrachten Arzneimittel6
Anzahl der klinischen Arzneimittel7Target-AliasPlatelet Glycoprotein GPIIb-IIIa Complex
Höchste Forschungs- und EntwicklungsphaseApproved
Englischer NameIntegrin alpha-IIb/beta-3
Target-AliasPlatelet Glycoprotein GPIIb-IIIa Complex
Anzahl der inverkehr gebrachten Arzneimittel6
Anzahl der klinischen Arzneimittel7
Höchste Forschungs- und EntwicklungsphaseApproved

Integrin alpha 2b beta 3 Produktliste

  • Attribut

    Protein (1)

  • Produktbibliothek

    Online (1)

  • Spezies

    Human (1)

  • Etikett

    His Tag (1)

  • Marker

    Unconjugated (1)

ProduktnummerSpeziesExpressionssystemProduktbeschreibungProteinstrukturReinheitEigenschaftenVorbestellen/Bestellen
Human
HEK293
Human Integrin alpha 2b beta 3 (ITGAIIb&ITGB3) Heterodimer Protein, His Tag&Tag Free, low endotoxin (MALS verified)
In den Warenkorb legen
Gesamtmenge1
  • 1

Integrin alpha 2b beta 3 Molekülhintergrund

Integrin alpha IIb beta 3 exist in a conformational equilibrium clustered around four main states. These conformations range from a compact bent nodule to two partially extended intermediate conformers and finally to a fully upright state. Activation of blood platelets by physiological stimuli at sites of vascular injury induces inside-out signaling, resulting in a conformational change of the prototype Integrin alpha IIb beta 3 from an inactive to an active state competent to bind soluble fibrinogen. Furthermore, ligand occupancy of Integrin alpha IIb beta 3 outside-in signaling and additional conformational changes of the receptor, leading to the exposure of extracellular neoepitopes termed ligand-induced binding sites (LIBS), which are recognized by anti-LIBS monoclonal antibodies.

Integrin alpha 2b beta 3 Molekülalias

Integrin alpha 2b beta 3,ITGAIIb&ITGB3

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
Zalunfiban acetateRUC-4; RUC-4 acetatePhase 3 ClinicalThe Rockefeller UniversityST Elevation Myocardial Infarction
Details
18F-GPIF18-GP1; 18F-GPI; GP1-F18; GP1-18F; [18F]GP1; [18F]GP-1Phase 2 ClinicalBayer AGAortic Aneurysm, Abdominal; Venous Thrombosis
Details
MT-1002(Shaanxi Micot Technology)MT-1002Phase 2 ClinicalShaanxi Micot Pharmaceutical Technology Co LtdAcute Coronary Syndrome; Angina, Unstable; Blood Coagulation Disorders; Non-ST Elevated Myocardial Infarction; ST Elevation Myocardial Infarction; Stroke; Thrombocytopenia; Thrombosis
Details
Pury PeptideMT-1001Phase 2 ClinicalShaanxi Micot Pharmaceutical Technology Co LtdAcute Coronary Syndrome
Details
BGC-728BGC-728Phase 2 ClinicalBtg PlcMyocardial Infarction; Stroke
Details
EGT-022EG-22; HU-005; EGT-022Phase 2 ClinicalEyegene IncPressure Ulcer
Details
HYC-11395HYC-11395Phase 1 ClinicalHefei Cosource Medicine Technology, Nanjing Heqi Pharmaceutical Technology Co LtdCoronary Artery Disease; Thromboembolism
Details

Inverkehr gebrachte Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaFrühestes MarkennameFrühestes GenehmigungslandFrüheste IndikationFrüheste GenehmigungsgesellschaftFrüheste GenehmigungsdatumIndikationenKlinische Studie
Tirofiban Hydrochloride HydrateL-462; MK-383; MK-0383; L-700462ApprovedMerck Sharp & Dohme Corp欣维宁, 艾卡特, AggrastatUnited StatesAcute Coronary Syndrome; Coronary Thrombosis; ThrombosisMedicure Inc1998-05-14Acute Coronary Syndrome; Angina, Unstable; Cardiovascular Diseases; Cerebral Infarction; Coronary Thrombosis; Ischemic Stroke; Myocardial Infarction; Renal Insufficiency; Stroke; Subarachnoid Hemorrhage; Thrombosis; Vascular Diseases
Details
Abciximab biosimilar (ISU Abxis)ISU-301ApprovedIsu Abxis Co LtdClotinab, FaximabMyocardial Infarction; Myocardial Ischemia
Details
Abciximabc7E3-Fab; c7E3-F(ab')2ApprovedEli Lilly And Company, Johnson & Johnson Innovative MedicineReoProUnited StatesMyocardial IschemiaJanssen Biotech Inc1994-12-22Acute Disease; Angina, Unstable; Arterial Occlusive Diseases; Brain Ischemia; Carotid Stenosis; Constriction, Pathologic; Myocardial Infarction; Myocardial Ischemia; Renal Artery Obstruction; ST Elevation Myocardial Infarction; Stroke
Details
Abciximab biosimilar (Reliance Life Sciences)R-TPR-019ApprovedReliance Life SciencesAbcixiRelIndiaAngina, Unstable; Myocardial IschemiaReliance Life Sciences2013-01-01Angina, Unstable; Myocardial Ischemia
Details
EptifibatideCN-102702321; Sch-60936; SB-1; C68-22ApprovedMillennium Pharmaceuticals IncIntegrelin (former Brand Name), IntegrilinEUAngina, Unstable; Myocardial InfarctionGlaxosmithkline (Ireland) Ltd1998-05-18Acute Coronary Syndrome; Anemia, Sickle Cell; Angina, Unstable; Ischemic Stroke; Myocardial Infarction; ST Elevation Myocardial Infarction
Details
Bevifibatide CitrateBAT-2094; BAT2094ApprovedBio-Thera Solutions Ltd贝塔宁, BETAGRINMainland ChinaAcute Coronary SyndromeBio-Thera Solutions Ltd2024-06-25Acute Coronary Syndrome; Angina Pectoris; Angina, Unstable; Myocardial Infarction; Myocardial Ischemia; Non-ST Elevated Myocardial Infarction; Thrombosis
Details
  • Molekülinformation
  • Produktliste
  • Inverkehr gebrachte Arzneimittelinformation
  • Klinische Arzneimittelinformation
Kontaktieren Sie uns